Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Novartis Withdraws U.S. and EU sNDAs for Zometa in Breast Cancer

Phase III study data failed to show benefits of adding drug to postsurgery chemo and hormone therapy.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

The Price of BRCA Testing

Is getting a genetic test worth the multi-thousand dollar price?

Suggest a Poll